- The company has partnered with Dermagate of Quebec, Canada, for the manufacture of ETST’s Hygee device, which tests women for sexually transmitted infections (STIs)
- ETST has started the qualification process for the Medical Device Single Audit Program (MDSAP), a new certification program, and plans to grow its portfolio of medical devices in 2019
- SeeThruEquity, LLC update projects that ETST will achieve $7.1 million in revenues by FY2020 as it grows its product line and expands into full spectrum cannabinoid beverages
Earth Science Tech, Inc. (OTCQB: ETST), a biotech company that markets and develops hemp cannabinoid (CBD) products, sees FY2019 as its pivotal expansion year. It is progressing in the development of its Hygee medical device, increasing its portfolio of devices and introducing two new nutraceutical products (http://ibn.fm/nezv1). It has formed a strategic partnership for Hygee’s manufacture with Dermagate, a company that specializes in the production of dermatology and wound care products.
The new partnership would also give ETST access to other medical devices that can be marketed in the future along with Hygee and Nanoderm, a unique wound care product that ETST distributes. Prior, ETST finalized an agreement with Groupe Opmedic Inc. and its Procrea Fertility Laboratories for lab services to detect STIs in women using Hygee (http://ibn.fm/ooaiI).
ETST, based in Doral, Florida, produces and sells CBD products, as well as dietary supplements for the pharmaceutical and nutraceutical fields. The company is focused on the cannabidiol, pharmaceutical and nutraceutical sectors, along with the development, through subsidiaries, of medical devices and research. ETST’s goal is to become a world leader in the CBD space.
Nickolas S. Tabraue, president, director and chairman of ETST, said in a news release that he expects certification of the Hygee device in Canada in early 2019. He and Gatan Houle, president and CEO of PharmaGate Group Inc. and Dermagate, expressed optimism that the MDSAP certification audit for Hygee manufacturing would begin as early as January 2019. He added that ETST would launch two new products for the nutraceutical market in 2019.
Both Tabraue and Dr. Michel Aubé, ETST’s CEO and chief science officer, believe that Health Canada’s requirement that the new MDSAP certification be attained by manufacturers in the new year is a positive marketing development for ETST. They believe that it will thin the field of smaller manufacturers who are unable to meet the standard. It is seen as giving ETST an opportunity to expand its product portfolio with existing products that would need new distributors, the company said.
A benefit is that ETST, under the new regulations, will be able to audit Hygee for up to five different medical device markets, including Australia, Brazil, Canada, Japan and the United States. These represent part of the company’s target market. STIs are a worldwide problem. Tabraue said that he expects Hygee to be certified by mid-2019 in other countries, too, seeking to adopt the new accreditation and facilitate the commercialization of medical devices.
SeeThruEquity sees ETST’s participation in the booming CBD industry, focusing on the hemp-derived segment, enabling it to reach revenues of $7.1 million by FY2020. The research report described its diversity, including its line of nutraceuticals and pharmaceuticals, TV campaign and uplisting to the OCTQB Venture Market (http://ibn.fm/omeQM).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. ETST also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
